Trial
NCT04109690
CPX-351 in Patients Treated for Higher-risk Myelodysplastic Syndromes Experiencing Hypomethylating Agent Failure.
Phase IWITHDRAWNSAFETYConfidence: MEDIUM
Sponsor
Yale University
Collaborators
—
Condition
MDS
Intervention
CPX-351
Why stopped
Failure to enroll
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-01-24